Sigyn Therapeutics, Inc.
SIGY
$3.53
-$0.62-14.94%
OTC PK
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -36.26% | 66.20% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -40.88% | 34.12% | |||
| Operating Income | 40.88% | -34.12% | |||
| Income Before Tax | 56.32% | -38.79% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 56.32% | -38.79% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 56.32% | -38.79% | |||
| EBIT | 40.88% | -34.12% | |||
| EBITDA | 40.95% | -34.20% | |||
| EPS Basic | 65.19% | -35.45% | |||
| Normalized Basic EPS | 62.60% | -35.45% | |||
| EPS Diluted | 64.80% | -34.77% | |||
| Normalized Diluted EPS | 62.60% | -35.45% | |||
| Average Basic Shares Outstanding | 25.48% | 2.48% | |||
| Average Diluted Shares Outstanding | 25.48% | 2.48% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||